Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: MenQuadfi (Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid) — Sanofi Winthrop Industrie
EMA has authorised MenQuadfi, a meningococcal vaccine combination covering groups A, C, W-135, and Y (tetanus toxoid-conjugated), for mening…
-
EMA approval · 2026-07-10EMA Authorised: Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) — GSK Vaccines S.r.l.
The European Medicines Agency has authorised Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine by GSK Vaccines S.r.l., for i…
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Results: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants [Phase 2]
Phase 2 study assessing safety, tolerability, and immune response of a meningococcal ABCWY vaccine in healthy infants; results posted after …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents [Phase 2]
Phase 2 clinical trial update evaluating safety, tolerability, and immunogenicity of the MenABCWY vaccine administered on different dosing s…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years [Phase 3]
A Phase 3 clinical trial evaluating Sinovac's Group ACYW135 meningococcal conjugate vaccine in children aged 2-6 years; the study is current…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months [Phase 3]
Phase 3 study evaluating Group ACYW135 meningococcal conjugate vaccine in children aged 12-23 months; the trial is currently not yet recruit…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months [Phase 3]
Phase III trial of a meningococcal conjugate vaccine (groups A, C, Y, W-135) in infants aged 3-5 months, status not yet recruiting.
-
EMA approval · 2026-03-24EMA Authorised: MenQuadfi (Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid) — Sanofi Winthrop Industrie
The European Medicines Agency authorised MenQuadfi, a tetravalent meningococcal conjugate vaccine (serogroups A, C, W-135 and Y) manufacture…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14 [NA]
A study evaluating nasal inoculation with Neisseria lactamica to assess colonization and immunogenicity was terminated. Results were posted …
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants [Phase 3]
Phase 3 safety and immunogenicity study of co-administering GSK Meningococcal Group B Vaccine with a 13-valent pneumococcal vaccine and rout…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
An update on a clinical trial evaluating antibody persistence beyond five years after vaccination with MenFive (NmCV-5), a pentavalent menin…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa [Phase 3]
Phase 3 trial evaluating MenACYW Conjugate Vaccine co-administered with routine pediatric vaccines in healthy infants and toddlers in India …
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the safety and immunogenicity of an investigational pentavalent meningococcal ABCYW vaccine in pediatric partic…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents [Phase 1, Phase 2]
This document notes the completion of a Phase 1/Phase 2 trial of an investigational pentavalent meningococcal ABCYW vaccine in adults and ad…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine [Phase 1]
This is a Phase 1 clinical trial evaluating an adsorbed, acellular pertussis vaccine component combined with Hib and ACWY meningococcal comp…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug [Phase 3]
Phase 3 clinical trial comparing immunogenicity, reactogenicity, and safety of GNG-DE versus a reference drug for meningococcal disease. The…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults [Phase 4]
A Phase 4 clinical trial evaluating MenB-FHbp alone or combined with MenACWY-TT in young adults primed with MenB-4C is currently recruiting.
-
EMA approval · 2025-12-17EMA Authorised: Trumenba (Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B) — Pfizer Europe MA EEIG
The EMA has authorised Trumenba, a vaccine against meningococcal disease caused by Neisseria meningitidis serogroup B, for use in Europe.
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers [Phase 3]
A Phase 3 trial evaluating the immunogenicity and safety of a Meningococcal ACYW Conjugate Vaccine in healthy infants and toddlers has been …
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
An observational, passive surveillance study in the United States to collect information on pregnancies exposed to the MenQuadfi meningococc…
-
EMA approval · 2025-10-14EMA Authorised: Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine) — GSK Vaccines S.r.l.
EMA authorised Menveo, a meningococcal group A, C, W-135 and Y conjugate vaccine, for immunization against meningococcal disease. The decisi…
-
FDA approval · 2025-10-08FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Rifadin IV (rifampin) submitted by Sanofi-Aventis U.S. LLC. This action covers the intraveno…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy [Phase 4]
Phase 4 study evaluating immunogenicity and safety of MenQuadfi as a booster in toddlers aged 12 to 23 months, regardless of prior infancy p…
-
EMA approval · 2025-08-01EMA Authorised: Bexsero (outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254);recombinant Neisseria meningitidis group B fHbp fusion protein;recombinant Neisseria meningitidis group B NadA protein;recombinant Neisseria meningitidis group B NHBA fusion protein) — GSK Vaccines S.r.l.
The European Medicines Agency authorised Bexsero, a meningococcal group B vaccine produced by GSK Vaccines S.r.l., for use in Europe. The va…
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population [Phase 3]
A Phase 3 trial of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) in 4- to 6-year-old children has complet…